Essex Bio-Technology Limited (HKG:1061)

Market Cap	1.21B -57.4%
Revenue (ttm)	1.72B +0.2%
Net Income	265.41M -15.3%
EPS	0.47 -15.0%
Shares Out	564.91M
PE Ratio	4.59
Forward PE	3.77
Dividend	0.14 (6.51%)
Ex-Dividend Date	Aug 18, 2026

Volume	38,000
Open	2.065
Previous Close	2.085
Day's Range	2.060 - 2.150
52-Week Range	2.010 - 5.100
Beta	-0.01
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 5, 2026

About Essex Bio-Technology

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. It operates through Ophthalmology, Surgical, and Healthcare and Partner Services segments. The company researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration. It offers Beifushu series, such as Beifushu eye drops, eye gel, and unit-dose eye drops to treat ocular wounds; and Tobramycin, Levofloxacin, Sodium Hyaluronate...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 1,240
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1061

Financial Performance

In 2025, Essex Bio-Technology's revenue was 1.81 billion, an increase of 8.62% compared to the previous year's 1.67 billion. Earnings were 318.09 million, an increase of 3.54%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error